News & Updates

Minimal monitoring approach of HCV treatment delivers acceptable SVR

22 Mar 2021 by

A minimal monitoring (MINMON) approach to treatment of hepatitis C virus (HCV) infection with sofosbuvir/velpatasvir appeared to render an acceptable sustained virological response (SVR), according to results of the phase IV ACTG* A5360 trial.

Minimal monitoring approach of HCV treatment delivers acceptable SVR

22 Mar 2021

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

12 Mar 2021 by

Longer-term follow-up after the final analysis of the KEYNOTE-240* trial showed that improvements in overall survival (OS) and progression-free survival (PFS) with pembrolizumab were maintained in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib, according to updated results of the trial presented at ASCO GI 2021.

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

12 Mar 2021

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021 by

Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021

NAFLD screening recommended in overweight, obese kids with T1D

06 Mar 2021

Nonalcoholic fatty liver disease (NAFLD) does not seem to occur at elevated rates among children and young adults with type 1 diabetes (T1D) but shows signals among those overweight or obese, reports a new study.

NAFLD screening recommended in overweight, obese kids with T1D

06 Mar 2021

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

05 Mar 2021 by

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

05 Mar 2021

Modified Mediterranean diet halves NAFLD risk

26 Feb 2021 by

A modification of the Mediterranean diet (MED), otherwise called green-MED, may reduce the risk of developing NALFD*, the DIRECT PLUS** trial suggests.

Modified Mediterranean diet halves NAFLD risk

26 Feb 2021

Statins yield cancer survival gains in NAFLD patients

26 Feb 2021

Among patients with nonalcoholic fatty liver disease (NAFLD), use of statins considerably reduces cancer-related mortality, a study has found.

Statins yield cancer survival gains in NAFLD patients

26 Feb 2021

Unrestricted DAA use could reduce HCV incidence in HIV

25 Feb 2021 by

Unrestricted access to direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection in individuals with HIV led to a substantial reduction in HCV incidence, particularly in the key subgroup of men who have sex with men (MSM), according to a retrospective Dutch study.

Unrestricted DAA use could reduce HCV incidence in HIV

25 Feb 2021

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

24 Feb 2021 by

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not result in worsening renal function or bone mineral density (BMD) in Asian patients with chronic hepatitis B virus (HBV) infection, according to a small real-world prospective study.

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

24 Feb 2021

Cirrhosis tied to worse survival among COVID-19 patients

24 Feb 2021

Cirrhosis is associated with poorer survival among chronic liver disease (CLD) patients with the novel coronavirus disease (COVID-19), a recent study has found. Such association is more pronounced in those with more advanced cirrhosis or with alcohol-related liver diseases.

Cirrhosis tied to worse survival among COVID-19 patients

24 Feb 2021

News & Updates

Filter by Specialty:

Specialty:

Minimal monitoring approach of HCV treatment delivers acceptable SVR

Minimal monitoring approach of HCV treatment delivers acceptable SVR

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

GI cancer patients could continue therapy during COVID-19 pandemic

GI cancer patients could continue therapy during COVID-19 pandemic

NAFLD screening recommended in overweight, obese kids with T1D

NAFLD screening recommended in overweight, obese kids with T1D

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

Modified Mediterranean diet halves NAFLD risk

Modified Mediterranean diet halves NAFLD risk

Statins yield cancer survival gains in NAFLD patients

Statins yield cancer survival gains in NAFLD patients

Unrestricted DAA use could reduce HCV incidence in HIV

Unrestricted DAA use could reduce HCV incidence in HIV

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

Cirrhosis tied to worse survival among COVID-19 patients

Cirrhosis tied to worse survival among COVID-19 patients